256 related articles for article (PubMed ID: 26174441)
1. Metabolomic profiling for the identification of novel diagnostic markers in prostate cancer.
Lucarelli G; Rutigliano M; Galleggiante V; Giglio A; Palazzo S; Ferro M; Simone C; Bettocchi C; Battaglia M; Ditonno P
Expert Rev Mol Diagn; 2015; 15(9):1211-24. PubMed ID: 26174441
[TBL] [Abstract][Full Text] [Related]
2. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression.
Sreekumar A; Poisson LM; Rajendiran TM; Khan AP; Cao Q; Yu J; Laxman B; Mehra R; Lonigro RJ; Li Y; Nyati MK; Ahsan A; Kalyana-Sundaram S; Han B; Cao X; Byun J; Omenn GS; Ghosh D; Pennathur S; Alexander DC; Berger A; Shuster JR; Wei JT; Varambally S; Beecher C; Chinnaiyan AM
Nature; 2009 Feb; 457(7231):910-4. PubMed ID: 19212411
[TBL] [Abstract][Full Text] [Related]
3. Metabolomic profiling reveals a role for androgen in activating amino acid metabolism and methylation in prostate cancer cells.
Putluri N; Shojaie A; Vasu VT; Nalluri S; Vareed SK; Putluri V; Vivekanandan-Giri A; Byun J; Pennathur S; Sana TR; Fischer SM; Palapattu GS; Creighton CJ; Michailidis G; Sreekumar A
PLoS One; 2011; 6(7):e21417. PubMed ID: 21789170
[TBL] [Abstract][Full Text] [Related]
4. Metabolomics approaches and applications in prostate cancer research.
Zhang A; Yan G; Han Y; Wang X
Appl Biochem Biotechnol; 2014 Sep; 174(1):6-12. PubMed ID: 24838846
[TBL] [Abstract][Full Text] [Related]
5. Serum metabolomic profiling of prostate cancer risk in the prostate, lung, colorectal, and ovarian cancer screening trial.
Huang J; Mondul AM; Weinstein SJ; Koutros S; Derkach A; Karoly E; Sampson JN; Moore SC; Berndt SI; Albanes D
Br J Cancer; 2016 Oct; 115(9):1087-1095. PubMed ID: 27673363
[TBL] [Abstract][Full Text] [Related]
6. Metabolomic Biomarkers of Prostate Cancer: Prediction, Diagnosis, Progression, Prognosis, and Recurrence.
Kelly RS; Vander Heiden MG; Giovannucci E; Mucci LA
Cancer Epidemiol Biomarkers Prev; 2016 Jun; 25(6):887-906. PubMed ID: 27197278
[TBL] [Abstract][Full Text] [Related]
7. Comparative Metabolomic and Lipidomic Analysis of Phenotype Stratified Prostate Cells.
Burch TC; Isaac G; Booher CL; Rhim JS; Rainville P; Langridge J; Baker A; Nyalwidhe JO
PLoS One; 2015; 10(8):e0134206. PubMed ID: 26244785
[TBL] [Abstract][Full Text] [Related]
8. Metabolic signatures of malignant progression in prostate epithelial cells.
Teahan O; Bevan CL; Waxman J; Keun HC
Int J Biochem Cell Biol; 2011 Jul; 43(7):1002-9. PubMed ID: 20633696
[TBL] [Abstract][Full Text] [Related]
9. GC/MS-based metabolomic approach to validate the role of urinary sarcosine and target biomarkers for human prostate cancer by microwave-assisted derivatization.
Wu H; Liu T; Ma C; Xue R; Deng C; Zeng H; Shen X
Anal Bioanal Chem; 2011 Aug; 401(2):635-46. PubMed ID: 21626193
[TBL] [Abstract][Full Text] [Related]
10. Metabolomic signatures of aggressive prostate cancer.
McDunn JE; Li Z; Adam KP; Neri BP; Wolfert RL; Milburn MV; Lotan Y; Wheeler TM
Prostate; 2013 Oct; 73(14):1547-60. PubMed ID: 23824564
[TBL] [Abstract][Full Text] [Related]
11. Integration of Metabolomics and Transcriptomics Reveals Major Metabolic Pathways and Potential Biomarker Involved in Prostate Cancer.
Ren S; Shao Y; Zhao X; Hong CS; Wang F; Lu X; Li J; Ye G; Yan M; Zhuang Z; Xu C; Xu G; Sun Y
Mol Cell Proteomics; 2016 Jan; 15(1):154-63. PubMed ID: 26545398
[TBL] [Abstract][Full Text] [Related]
12. NMR-based metabolomics of prostate cancer: a protagonist in clinical diagnostics.
Kumar D; Gupta A; Nath K
Expert Rev Mol Diagn; 2016 Jun; 16(6):651-61. PubMed ID: 26959614
[TBL] [Abstract][Full Text] [Related]
13. Recent advances in metabolomics in oncology.
O'Connell TM
Bioanalysis; 2012 Feb; 4(4):431-51. PubMed ID: 22394143
[TBL] [Abstract][Full Text] [Related]
14. Metabolomic profiling of hormone-dependent cancers: a bird's eye view.
Lloyd SM; Arnold J; Sreekumar A
Trends Endocrinol Metab; 2015 Sep; 26(9):477-85. PubMed ID: 26242817
[TBL] [Abstract][Full Text] [Related]
15. Sarcosine and other metabolites along the choline oxidation pathway in relation to prostate cancer--a large nested case-control study within the JANUS cohort in Norway.
de Vogel S; Ulvik A; Meyer K; Ueland PM; Nygård O; Vollset SE; Tell GS; Gregory JF; Tretli S; Bjørge T
Int J Cancer; 2014 Jan; 134(1):197-206. PubMed ID: 23797698
[TBL] [Abstract][Full Text] [Related]
16. Metabolomic profiling for the identification of novel diagnostic markers and therapeutic targets in prostate cancer: an update.
Lucarelli G; Loizzo D; Ferro M; Rutigliano M; Vartolomei MD; Cantiello F; Buonerba C; Di Lorenzo G; Terracciano D; De Cobelli O; Bettocchi C; Ditonno P; Battaglia M
Expert Rev Mol Diagn; 2019 May; 19(5):377-387. PubMed ID: 30957583
[TBL] [Abstract][Full Text] [Related]
17. Cell metabolomics identify regulatory pathways and targets of magnoline against prostate cancer.
Sun H; Zhang AH; Liu SB; Qiu S; Li XN; Zhang TL; Liu L; Wang XJ
J Chromatogr B Analyt Technol Biomed Life Sci; 2018 Dec; 1102-1103():143-151. PubMed ID: 30391728
[TBL] [Abstract][Full Text] [Related]
18. [Analysis of the metabolome suggests a major potential role of sarcosine in the progression of cancer of the prostate].
Darbon JM
Bull Cancer; 2009 Apr; 96(4):355-6. PubMed ID: 19562840
[No Abstract] [Full Text] [Related]
19. Identification of the perturbed metabolic pathways associating with prostate cancer cells and anticancer affects of obacunone.
Xie J; Zhang AH; Qiu S; Zhang TL; Li XN; Yan GL; Sun H; Liu L; Wang XJ
J Proteomics; 2019 Aug; 206():103447. PubMed ID: 31326558
[TBL] [Abstract][Full Text] [Related]
20. Metabolomics-Based Biosignatures of Prostate Cancer in Patients Following Radiotherapy.
Nalbantoglu S; Abu-Asab M; Suy S; Collins S; Amri H
OMICS; 2019 Apr; 23(4):214-223. PubMed ID: 31009330
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
